Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement.
Pan Y, Xue Q, Yang Y, Shi T, Wang H, Song X, Luo Y, Liu W, Ren S, Cai Y, Nie Y, Song Z, Liu B, Li JP, Wei J.
Pan Y, et al. Among authors: li jp.
Cell Rep Med. 2024 Jun 18;5(6):101590. doi: 10.1016/j.xcrm.2024.101590. Epub 2024 Jun 5.
Cell Rep Med. 2024.
PMID: 38843844